Pfizer Inc. (PFE) Rating Increased to Strong-Buy at Vetr Inc.
Pfizer Inc. (NYSE:PFE) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday. The firm currently has a $37.42 target price on the biopharmaceutical company’s stock. Vetr‘s price target suggests a potential upside of 15.14% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. Argus reissued a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research report on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Citigroup Inc. reissued a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday, August 3rd. Barclays PLC reissued an “equal weight” rating and issued a $34.00 price target on shares of Pfizer in a research report on Tuesday, August 2nd. Finally, Jefferies Group set a $40.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 1st. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. Pfizer has an average rating of “Buy” and an average price target of $38.63.
Shares of Pfizer (NYSE:PFE) traded down 0.49% during midday trading on Monday, reaching $32.50. The company had a trading volume of 16,923,468 shares. The firm’s 50 day moving average price is $33.95 and its 200-day moving average price is $34.35. The company has a market capitalization of $197.13 billion, a P/E ratio of 28.81 and a beta of 0.86. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the business posted $0.56 earnings per share. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts anticipate that Pfizer will post $2.46 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a yield of 3.69%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Large investors have recently bought and sold shares of the company. Nelson Roberts Investment Advisors LLC raised its stake in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC purchased a new stake in Pfizer during the second quarter valued at $110,000. Tuttle Tactical Management LLC purchased a new stake in Pfizer during the second quarter valued at $117,000. Gierl Augustine Investment Management Inc raised its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares during the period. Finally, Catamount Wealth Management raised its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the period. Institutional investors own 69.66% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.